FACULTY

MEET OUR FACULTY

Prof. Praveen T. K

PROF. PRAVEEN T. K

Professor & Principal
Profile

Prof. Praveen T. K., M.Pharm. is a senior academician and researcher currently serving as Professor and Principal, Department of Pharmacology, at the College of Pharmacy, JSS University, Noida. He has over 22 years of experience in teaching, research, academic leadership, and institutional development in pharmaceutical sciences. He earned his Ph.D. in Pharmaceutical Sciences from The Tamil Nadu Dr. M.G.R. Medical University, Chennai, after completing his M.Pharm in Pharmacology and B.Pharm from Rajiv Gandhi University of Health Sciences, Bengaluru. His research interests include cancer pharmacology, metabolic and neuropharmacological disorders, nano-based drug delivery systems, and computer-aided drug design, with an emphasis on translational research. Prof. Praveen has published more than 150 research articles in reputed national and international journals and has received extramural research funding exceeding ₹32.8 lakhs as Principal Investigator from agencies such as DST, DBT, SERB, BIRAC, ICMR, and UGC. He also holds two granted patents and has guided 40 M.Pharm dissertations and 17 Ph.D. scholars. He teaches postgraduate courses, serves as an expert reviewer and CPCSEA nominee, and is an active member of leading professional bodies. His contributions have been recognized with several academic and research awards.

Email

Email Id

praveen.tk@jssuninoida.edu.in
LinkedIn

LinkedIn Profile

www.linkedin.com/in/praveen-thaggikuppe-krishnamurthy-94814019/
Education
  • Ph.D., (Pharmaceutical Sciences), The Tamil Nadu Dr. MGR Medical University, Chennai. (2013)
  • Master of Pharmacy in Pharmacology, Rajiv Gandhi University of Health Sciences, Bangalore. (2003)
  • Bachelor of Pharmacy, Rajiv Gandhi University of Health Sciences, Bangalore. (2000)
Research

research-iconGoogle Scholar

research-iconORC iD

research-iconScopus

Awards & Recognition
  • Received Research Excellence Award-2025, from JSS Academy of Higher Education & Research, Mysuru.
  • Received a “Certificate of appreciation for the advancement of research at JSS College of Pharmacy, Ooty-2019” from JSS Academy of Higher Education & Research, Mysuru.
  • Received “Recognition of Achievements-Acquiring External Funding” from JSS College of Pharmacy, Ooty, for the academic year 2018-19. (Date: 20-3-2019)
  • Received “Best Teacher Award-2018” from JSS College of Pharmacy, Ooty (Date: 20-3-2019)
  • Permanent honorary Membership Award-faculty board-The University of Khartoum, Sudan.
  • CPCSEA Nominee-Ministry of Forest and Environment, Govt. of India, New Delhi.
  • Expert Reviewer-Web based Submission, Processing & Management for Extramural Proposals, ICMR, New Delhi
  • Research Advisory Committee Member-Adichunchanagiri University, Mandya, Karnataka
  • Member of “Advisory Board” for "Experimental Pharmacology (Ex-Pharm) Series Software" from Bureau for Health and Education (Reg. No: 17D0105798).
Experience
  • 22 years
Research Interests
  • Metabolic disorders
  • Cancer research
  • Neuropharmacology
  • Nano-drug delivery systems
  • Computer Aided Drug Design
Publications
  • Kumari M, Piyongsola, Ravi Naik M, Singh Rathore H, Kumar Shukla A, Iqbal Dar A, Praveen TK. Targeted delivery of DAPT using dual antibody functionalized solid lipid nanoparticles for enhanced anti-tumour activity against triple negative breast cancer. International Journal of Pharmaceutics. 2025;670. [Impact factor: 5.3]
  • Vasudevan Sajini D, Praveen TK, Chakkittukandiyil A, Mudavath RN. Orientin Modulates Nrf2-ARE, PI3K/Akt, JNK-ERK1/2, and TLR4/NF-kB Pathways to Produce Neuroprotective Benefits in Parkinson's Disease. Neurochemical Research. 2024;49(6):1577-87. [Impact factor: 4.4]
  • Varshini MS, Reddy RA, Praveen TK, Wadhwani A. Harmony of Wnt pathway in Alzheimer's: Navigating the multidimensional progression from preclinical to clinical stages. Neuroscience & Biobehavioral Reviews. 2024;165. [Impact factor: 7.5]
  • Singh MT, Praveen TK, Magham SV. Harnessing the synergistic potential of NK1R antagonists and selective COX-2 inhibitors for simultaneous targeting of TNBC cells and cancer stem cells. Journal of Drug Targeting. 2024;32(3):258-69. [Impact factor: 4.5]
  • Deepika NP, Praveen TK, Varshini MS, Naik MR, Sajini DV, Kiran AVVVR, et al. Ethnopharmacological validation of Karkataka Taila-An edible crab Rasayana in rotenone-induced in vitro and in vivo models of Parkinson's disease. Journal of Ethnopharmacology. 2024;335. [Impact factor: 4.30]
  • Praveen TK, Gangadharappa HV, Abu Lila AS, Moin A, Mehmood K, Krishna KL, et al. Inflammation targeted nanomedicines: Patents and applications in cancer therapy. Seminars in Cancer Biology. 2022;86:645-63. [Impact Factor: 15.71]
  • Manandhar S, Pai KSR, Praveen TK, Kiran AVVVR, Kumari GK. Identification of novel TMPRSS2 inhibitors against SARS-CoV-2 infection: a structure-based virtual screening and molecular dynamics study. Structural Chemistry. 2022;33(5):1529-41. [Impact Factor: 1.89]
  • Garikapati KK, Ammu V. V. V RK, Praveen TK, S. T N, B B, Nagappan K. Quantification of rosiglitazone in rat plasma and tissues via LC–MS/MS: Method development, validation, and application in pharmacokinetic and tissue distribution studies. Biomedical Chromatography. 2022;36(5). [Impact Factor: 1.92]
  • Pindiprolu SKSS, Praveen TK, Dev C, Chintamaneni PK. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer. Chemistry and Physics of Lipids. 2021;235. [Impact Factor: 3.33]
  • Kiran AVVVR, Kumari GK, Praveen TK. Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer. Investigational New Drugs. 2021;40(1):1-9. [Impact Factor: 3.85]
Grants
  • Co-Principal Investigator for the BIRAC BioNEST proposal entitled “BioNEST: JSS ATE Science & Technology Entrepreneurs Park”, (Total cost INR 893.11 Lakhs, Ref. No.: SPED-11/23/2024-SPED, May 5, 2025, Duration-60 months)
  • Principal Investigator for the DST-SERB-CRG project, “CD44 mAb Engineered Surface Modified Poly(lactic-co-glycolic acid) (PLGA) Polymeric Nanoparticles Loaded with Aprepitant and Etoricoxib for Simultaneous Targeting of TNBC Stem Cells and Cancer Cells [CRG/2023/002585, Date: June 2024], Total grant amount approved Rs. 39,27lakhs)
  • Principal Investigator for the DST sponsored Project “CD133 mAbs surface-modified carbon nanotubes loaded with survivin siRNA and Paclitaxel for the treatment of non-small cell lung cancer” (INT/UZBEK/P-01, Date: 09-2-2021), Total grant amount approved Rs. 117 lakhs)
  • Principal Investigator for the DBT sponsored Twining Project (Twinning Programme 2017-18) “Death receptor-5 targeted lipid nanoparticles of γ-secretase inhibitor for simultaneous targeting of breast cancer cells and cancer stem cells” (BT/PR24607/NER/95/772/2017, Total grant amount approved Rs. 48.73 lakhs)
  • Principal Investigator for the DST-Nannomission sponsored research project “Adipocyte specific delivery of oral thiazolidinedione nanoparticles functionalized with RGD and P3 peptides to reduce side effects and improve efficacy” (DST/NM/NB/2018/227, Total grant amount approved Rs. 51.00 lakhs)
  • Principal Investigator for the DBT sponsored Major Research Project entitled “Neuroprotection by nanoallosteric potentiators of M1 muscarinic acetylcholine receptors for reversal learning manageent in Alzheimer’s disease” (BT/PR9979/NNT/28/7052013, Total grant amount-Rs. 72,19,600/- Project duration 3-years, w.e.f. 27-3-2015)
  • Co-Investigator for DST Builder Level –II project, JSSAHER, Mysuru, (Total grant amount-Rs. 4,17,98,560/- Project duration 5-years, w.e.f. 22-11-2021)
  • Co-Investigator for the ICMR supported Research Project entitled “Therapeutic efficacy of selected probiotics and expression/suppression of proteins in triple negative breast cancer cells - A role of probiotics in cancer therapy”
  • Co-Investigator for the ICMR supported Research Project entitled “Nutrikinetic assessment of Iron: an Essential micronutrient isolated from fortified and biofortifies Indian based wheat cultivars” (Total grant amount-Rs. 32,60,000/- Project duration 3-years, w.e.f. April-1-2020, ID- 2020-5454)
  • Co-ordinator “Fund for Improvement of S&T Infrastructure in Universities and Higher Educational Institutions (FIST)” DST, New Delhi (FIST Sl.No. 23, dated April 22, 2015). (Total grant amount-Rs. 84,00,000/-. Project duration 2-years, w.e.f. 22-4-2015)
  • Co-Investigator for the UGC supported Major Research Project entitled “Design synthesis and evaluation of some novel dipeptidyl peptidase IV inhibitors as antidiabetic agents” (Total grant amount-Rs. 10,86,800/-. Project duration 3-years, w.e.f. 1-2-2011)
Patents
  • Patent No.: 38288: Novel Glitazones as PPAR alpha and PPAR gamma agonists and alpha glucosidase inhibitors” Application No. 2266/CHE/2012; Status: Granted on 26-11-2021
  • Patent No.: 388590: Surface Modified Benzyl quinolone carboxylic acid- Stearylamine Conjugates for management of Alzheimer’s disease Application No. 201941025298, Status: Granted on 7-2-2022.
  • Method of obtaining a solution of carbon nanoparticles by electrochemical oxidation of graphite electrodes" Intellectual Property Agency of the Republic of Uzbekistan. IAP № 20210349 of 02.07.2021, Status: Applied.
  • Solid Lipid Nanocarriers of Surface Modified Niclosamide for targeting of Sialic Acid Receptors. Application No. 201941031322; Status: Published
  • Tissue engineered acellular scaffold for the treatment of diabetic wounds. Application No.: 202041027368; Status: Published.
  • Process for bioassay guided fractionation of M. Oleifera L. leaves to isolate Niazirin. Application No.: 2021410229028; Status: Applied.
  • Pioglitazone Nanoparticles functionalized with RGD and P3 Peptides and compositions thereof for Adipocyte Specific Drug Delivery." Patent Appl. No. 202241017503. Status: Applied on 29-Mar-2022.
  • Dual Antibody Conjugated Lipidic Nanoparticles of DAPT to Target Triple Negative Breast Cancer Cells." Patent Appl. No. 202241022997 Status: Applied on 27-April-2022.
  • Lyophilized Surface Modified Formoterol-Stearylamine Solid Lipid Nanoparticles and Compositions Thereof. (Patent Appl. No. 202241023744 Status: Applied on 29-April-2022)
  • 1,3,4-Thiadiazolo (3,2-Α) Pyrimidine-6-Carbonitrile compounds as PARP1 Inhibitors (Patent Appl. No. 202141032777 Status: Applied on 21.07.2021)
  • 2-(1-substituted-1H-benzo[d]imidazol-2-yl)-N acetamide compounds having dual inhibitory activity. Patent Appl. No. 202141042924 Status: Applied on 22.09.2021.
  • 3-(5-benzyl-1, 3, 4-oxadiazol-2-yl)-2-substituted phenyl thiazolidin-4-one, as sirt-3 activators, and process for preparation thereof. Patent Appl. No. 202241003547 A Status: Published Applied on 21/01/2022.
Courses Taught Mention program name followed by subjects taught- please mention only subjects allotted as per your annual workload
  • M. Pharm
  • Cellular Molecular Pharmacology
  • Principles of Drug Discovery
Supervision
  • M.Pharm-40
  • PhD-17 (Completed-14; Ongoing-3)
Professional Memberships
  • Life Member- Indian Pharmacological Society (LP480)
  • Life Member- The Indian Pharmaceutical Association (TN/NIL/ON/LM/000472)
  • Life Member-Association of Pharmaceutical Teachers of India (KA/LM-1207)
  • Member: American Society for Pharmacology and Experimental Therapeutics (ASPET)
Conference / Workshops Attended / Invited Talks
  • Conferences: 60
  • Invited Talks: 50
Back to Faculties